BioRestorative Therapies jumps after completing Phase 2 dosing for lead spine cell therapy

By: Quiver PriceTracker

Posted: 2 days ago / May 27, 2026 3:50 p.m. UTC

BRTX

BioRestorative Therapies (BRTX) is up 111.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a company announcement that the final patient has been dosed in the Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease. For early-stage biotech stocks, a “last patient dosed” milestone can reset expectations around upcoming catalysts and reduce operational risk, sometimes triggering sharp re-ratings.

Details:

The company disclosed completion of Phase 2 dosing (treatment administration) for BRTX-100, its lead regenerative spine program.

The Phase 2 study is described as fully enrolled, and the program is moving into blinded follow-up ahead of planned topline safety and efficacy results expected in Q2 2027.

Management framed the milestone as a transition from active dosing logistics to the next stage of clinical execution, which can be viewed as a de-risking event.

This could also be amplified by small-float dynamics and momentum trading common in clinical-stage microcap biotech following material trial updates.

Sources:

GlobeNewswire, BioRestorative Therapies Investor Relations, U.S. SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BRTX Hedge Fund Activity

We have seen 7 institutional investors add shares of $BRTX stock to their portfolio, and 8 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC added 209,408 shares (+717.2%) to their portfolio in Q1 2026, for an estimated $56,979
GEODE CAPITAL MANAGEMENT, LLC added 165,229 shares (+285.6%) to their portfolio in Q1 2026, for an estimated $44,958
UBS GROUP AG added 99,832 shares (+inf%) to their portfolio in Q1 2026, for an estimated $27,164
DRW SECURITIES, LLC removed 46,665 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $12,697
STONEX GROUP INC. removed 37,450 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $44,003
VIRTU FINANCIAL LLC removed 24,351 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $28,612
NAPIER FINANCIAL, LLC removed 17,142 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $4,664

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.